Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B.

Published on Jun 1, 2021in European Journal of Gastroenterology & Hepatology2.251
· DOI :10.1097/MEG.0000000000001794
Hye Yeon Chon1
Estimated H-index: 1
(Yonsei University),
Yeon Seok Seo28
Estimated H-index: 28
(KU: Korea University)
+ 39 AuthorsSeung Up Kim55
Estimated H-index: 55
(Yonsei University)
OBJECTIVE The liver stiffness-based risk prediction models predict hepatocellular carcinoma (HCC) development. We investigated the influence of antiviral therapy (AVT) on liver stiffness-based risk prediction model in patients with chronic hepatitis B (CHB). METHODS Patients with CHB who initiated AVT were retrospectively recruited from 13 referral Korean institutes. The modified risk estimation for hepatocellular carcinoma in chronic hepatitis B (mREACH-B) model was selected for the analysis. RESULTS Between 2007 and 2015, 1034 patients with CHB were recruited. The mean age of the study population (639 men and 395 women) was 46.8 years. During AVT, the mREACH-B score significantly decreased from the baseline to 3 years of AVT (mean 9.21 → 7.46, P   0.05). The proportion of high-risk patients (mREACH-B score ≥11) was significantly reduced from the baseline to 2 years of AVT (36.4% → 16.4%, P   0.05). The mREACH-B scores at baseline and 1 year of AVT independently predicted HCC development (hazard ratio = 1.209-1.224) (all P < 0.05). The cumulative incidence rate of HCC was significantly different at 5 years of AVT among risk groups (high vs. high-intermediate vs. low-intermediate vs. low) from baseline (4.5% vs. 3.2% vs. 1.5% vs. 0.8%) and 1 year (11.8% vs. 4.6% vs. 1.8% vs. 0.6%) (all P < 0.05, log-rank tests). CONCLUSIONS The mREACH-B score was dynamically changed during AVT. Thus, repeated assessment of the mREACH-B score is required to predict the changing risk of HCC development in patients with CHB undergoing AVT.
📖 Papers frequently viewed together
132 Citations
#1Ibrahim A. Hanouneh (Mayo Clinic)H-Index: 3
#2Naim Alkhouri (University of Texas at Austin)H-Index: 46
Last. Amit G. Singal (UTSW: University of Texas Southwestern Medical Center)H-Index: 62
view all 3 authors...
: Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death worldwide. Prognosis and treatment options largely depend on tumor stage at diagnosis, with curative treatments only available if detected at an early stage. However, two thirds of patients with HCC are diagnosed at a late stage and not eligible for cure. Therefore several liver professional societies recommend HCC surveillance using abdominal ultrasound with or without alpha fetoprotein in at-risk population...
20 CitationsSource
#1Peter R. Galle (University of Mainz)H-Index: 28
#2Alejandro Forner (European Organisation for Research and Treatment of Cancer)H-Index: 1
Last. Valérie VilgrainH-Index: 95
view all 8 authors...
Summary Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
4,706 CitationsSource
#1Mi Young Jeon (Yonsei University)H-Index: 7
#2Hye Won Lee (Yonsei University)H-Index: 22
Last. Sang Hoon Ahn (Yonsei University)H-Index: 69
view all 8 authors...
Background & Aims Several risk prediction models for hepatocellular carcinoma (HCC) development are available. We explored whether the use of risk prediction models can dynamically predict HCC development at different time points in chronic hepatitis B (CHB) patients. Methods Between 2006 and 2014, 1397 CHB patients were recruited. All patients underwent serial transient elastography at intervals of >6 months. Results The median age of this study population (931 males and 466 females) was 49.0 y...
18 CitationsSource
#1Byung Seok Kim (DCU: Catholic University of Daegu)H-Index: 10
#2Yeon Seok Seo (KU: Korea University)H-Index: 28
Last. Seung Up Kim (Yonsei University)H-Index: 55
view all 14 authors...
Background&Aims A subcirrhotic range of liver stiffness (sc-LS), assessed by transient elastography, is associated with better outcomes in patients with chronic hepatitis B (CHB). We investigated whether the achievement of sc-LS by antiviral therapy (AVT) reduced the risk of developing hepatocellular carcinoma (HCC) in patients with CHB-related advanced fibrosis or cirrhosis. Methods In total, 209 patients with CHB-related advanced fibrosis or cirrhosis, who received paired transient elastograph...
13 CitationsSource
#1Julie K. Heimbach (Mayo Clinic)H-Index: 61
#2Laura Kulik (NU: Northwestern University)H-Index: 65
Last. Jorge A. Marrero (UTSW: University of Texas Southwestern Medical Center)H-Index: 28
view all 9 authors...
Author(s): Heimbach, JK; Kulik, LM; Finn, RS; Sirlin, CB; Abecassis, MM; Roberts, LR; Zhu, AX; Murad, MH; Marrero, JA
1,379 CitationsSource
#1Yeon Seok Seo (KU: Korea University)H-Index: 28
#2Byoung Kuk Jang (KMU: Keimyung University)H-Index: 25
Last. Jung Il Lee (Yonsei University)H-Index: 20
view all 10 authors...
// Yeon Seok Seo 1, * , Byoung Kuk Jang 2, * , Soon Ho Um 1 , Jae Seok Hwang 2 , Kwang-Hyub Han 3 , Sang Gyune Kim 4 , Kwan Sik Lee 3 , Seung Up Kim 3 , Young Seok Kim 4 and Jung Il Lee 3 1 Department of Internal Medicine, Korea University, Seoul, Korea 2 Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea 3 Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea 4 Department of Internal Medicine, Soonc...
18 CitationsSource
#1Masao Omata (UTokyo: University of Tokyo)H-Index: 128
#2Ann-Lii Cheng (NTU: National Taiwan University)H-Index: 90
Last. Shiv Kumar SarinH-Index: 93
view all 21 authors...
Abstract There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia-Pacific region, where HCC is one of the leading public health problems. Since the "Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines" meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. ...
709 CitationsSource
#1Mi Young Jeon (Yonsei University)H-Index: 7
#2Hye Won Lee (Yonsei University)H-Index: 22
Last. Kwang Hyub Han (Yonsei University)H-Index: 89
view all 10 authors...
Background and Aims The risk of developing hepatocellular carcinoma (HCC) varies, even in the context of cirrhosis. We investigated the relationship between liver stiffness (LS) in subcirrhotic range, assessed via transient elastography (TE), and risk of HCC development in patients with chronic hepatitis B (CHB)-related cirrhosis.
13 CitationsSource
#1Ran Xu Zhu (HKU: University of Hong Kong)H-Index: 1
#2Wai-Kay Seto (HKU: University of Hong Kong)H-Index: 42
Last. Man-Fung Yuen (HKU: University of Hong Kong)H-Index: 93
view all 4 authors...
Hepatocellular carcinoma (HCC) is the predominant primary liver cancer in many countries and is the third most common cause of cancer-related death in the Asia-Pacific region. The incidence of HCC is higher in men and in those over 40 years old. In the Asia-Pacific region, chronic hepatitis B virus and hepatitis C virus infections are the main etiological agents; in particular, chronic hepatitis B infection (CHB) is still the major cause in all Asia-Pacific countries except for Japan. Over the p...
274 CitationsSource
#1Kyu Sik JungH-Index: 19
#2Seung Up Kim (Yonsei University)H-Index: 55
Last. Kwang Hyub Han (Yonsei University)H-Index: 89
view all 8 authors...
Several risk prediction models have been created to predict hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) occurrence, with promising results. However, their prognostic performances need to be validated in the era of antiviral therapy. From 2006 to 2011, patients with chronic HBV infection were recruited and those with a history of HCC or hepatic decompensation were excluded. At enrollment, liver stiffness (LS) was measured using transient elastography. We assessed the performanc...
63 CitationsSource
Cited By2
#1Jung Hyun Ji (Yonsei University)
#2Soo-Young Park (KNU: Kyungpook National University)H-Index: 39
Last. Beom Kyung Kim (Yonsei University)H-Index: 35
view all 12 authors...
CAGE-B and SAGE-B scores, consisting of age and fibrotic burden as cirrhosis and/or liver stiffness, were recently proposed to predict hepatocellular carcinoma (HCC) risk among Caucasian chronic hepatitis B (CHB) patients undergoing long-term antiviral therapy. We externally validated their predictive performances among an independent cohort from Asia, compared to other conventional prediction models. We consecutively recruited CHB patients with well-controlled viremia (serum HBV-DNA<2,000 IU/ml...
#1Hye Won Lee (Yonsei University)H-Index: 22
#2Hyun Woong Lee (Yonsei University)H-Index: 18
Last. Beom Kyung Kim (Yonsei University)H-Index: 35
view all 10 authors...
Background Dynamic changes in fibrosis markers occur under long-term antiviral treatment (AVT) for chronic hepatitis B. We evaluated prognostic values of on-treatment liver stiffness (LS) compared to ultrasonography findings and determined its optimal cutoff. Methods The cumulative probability of hepatocellular carcinoma (HCC) was assessed among 880 patients receiving entecavir or tenofovir for ≥2 years. LS was measured using transient elastography. Results After ≥2 years' AVT, the proportion of...